A cardiometabolic patient and microbiota

Authors

DOI:

https://doi.org/10.14739/2310-1210.2025.3.321475

Keywords:

intestinal microbiota, cardiovascular diseases, abdominal obesity, hypertension, diabetes mellitus, atherosclerosis, short-chain fatty acids, intestinal dysbiosis, probiotics, prebiotics

Abstract

Aim: to determine associations between the microbiota and a cardiometabolic patient’s condition and to identify key mechanisms of the microbiota influence on the cardiovascular system and metabolic profile based on summarizing the scientific literature.

Material and methods. A descriptive-comparative analysis was performed to study associations between cardiometabolic patient’s condition and microbiota. The work was based on a substantive review of modern scientific literature, which allowed us to identify key aspects of this interaction and its impact on metabolic and cardiovascular processes. To achieve the goal, the following research methods were used: search method, comparative analysis, methods of generalization and synthesis.

Results. The article presents the study results indicating the pathology development such as abdominal obesity, diabetes mellitus, atherosclerosis, and arterial hypertension induced by disturbances in the microbiota composition (dysbiosis). Studying the probiotic and prebiotic effects provides perspectives to correct dysbiosis and improve the intestinal microflora functions. Probiotics, such as Lactobacilli and Bifidobacteria, are capable of microbiota balance normalization, reducing the risk for cardiovascular complications, as well as improving lipid metabolism and reinforcing the intestinal barrier function. Prebiotics help stimulate the beneficial bacteria colonization and the production of key metabolites such as short-chain fatty acids.

Conclusions. The intestinal microbiota has been shown to play a key role in the development and progression of numerous pathological conditions, such as cardiovascular disease, obesity, diabetes mellitus, atherosclerosis, and hypertension. Its effects are mediated by mechanisms, including intestinal wall permeability variations, pro-inflammatory process activation, and metabolic activity alterations. One of the important factors is a decreased count of microorganisms that produce short-chain fatty acids, resulting in impaired metabolism and an increased risk for cardiometabolic diseases.

Author Biography

T. V. Bogoslav, Zaporizhzhia State Medical and Pharmaceutical University

MD, PhD, Associate Professor of the Department of Internal Diseases No. 1

References

  1. Reiter-Brennan C, Dzaye O, Davis D, Blaha M, Eckel RH. Comprehensive Care Models for Cardiometabolic Disease. Curr Cardiol Rep. 2021;23(3):22. doi: https://doi.org/10.1007/s11886-021-01450-1
  2. Marques MD, Pires R, Perdigao M, Sousa L, Fonseca C, Pinho LG, et al. Patient-centered care for patients with cardiometabolic diseases: An integrative review. J Pers Med. 2021;11(12):1289. doi: https://doi.org/10.3390/jpm11121289
  3. Melnychuk IO. [Gut microbiota and cardiometabolic risk factors in coronary artery disease patients with atrial fibrillation]. Klinichna ta profilaktychna medytsyna. 2023;(4):57-65. Ukrainian. doi: https://doi.org/10.31612/2616-4868.4(26).2023.09
  4. Wang L, Wang S, Zhang Q, He C, Fu C, Wei Q. The role of the gut microbiota in health and cardiovascular diseases. Mol Biomed. 2022;3(1):30. doi: https://doi.org/10.1186/s43556-022-00091-2
  5. He MQ, Wang JY, Wang Y, Sui J, Zhang M, Ding X, et al. High-fat diet-induced adipose tissue expansion occurs prior to insulin resistance in C57BL/6J mice. Chronic Dis Transl Med. 2020;6(3):198-207. doi: https://doi.org/10.1016/j.cdtm.2020.06.003
  6. Yaribeygi H, Farrokhi FR, Butler AE, Sahebkar A. Insulin resistance: Review of the underlying molecular mechanisms. J Cell Physiol. 2019;234(6):8152-61. doi: https://doi.org/10.1002/jcp.27603
  7. El-Mowafy M, Elgaml A, El-Mesery M, Sultan S, Ahmed TA, Gomaa AI, et al. Changes of Gut-Microbiota-Liver Axis in Hepatitis C Virus Infection. Biology (Basel). 2021;10(1):55. doi: https://doi.org/10.3390/biology10010055
  8. Marconcin P, Ihle A, Werneck AO, Gouveia ER, Ferrari G, Peralta M, et al. The Association of Healthy Lifestyle Behaviors with Overweight and Obesity among Older Adults from 21 Countries. Nutrients. 2021;13(2):315. doi: https://doi.org/10.3390/nu13020315
  9. Ward ZJ, Bleich SN, Cradock AL, Barrett JL, Giles CM, Flax C, et al. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. N Engl J Med. 2019;381(25):2440-50. doi: https://doi.org/10.1056/NEJMsa1909301
  10. Patterson E, Ryan PM, Cryan JF, Dinan TG, Ross RP, Fitzgerald GF, et al. Gut microbiota, obesity and diabetes. Postgrad Med J. 2016;92(1087):286-300. doi: https://doi.org/10.1136/postgradmedj-2015-133285
  11. Tomasics G, Schandl L, Polyák A, Winkler GA. diabetes mellitus és a bélmikrobiom. Orvosi Hetilap. 2023;164(25):981-7. doi: https://doi.org/10.1556/650.2023.32788
  12. Liu J, Tan Y, Cheng H, Zhang D, Feng W, Peng C. Functions of Gut Microbiota Metabolites, Current Status and Future Perspectives. Aging Dis. 2022;13(4):1106-26. doi: https://doi.org/10.14336/AD.2022.0104
  13. Stepanov YM, Budzak IY. [Nature of intestinal microflora disorders in cardiovascular diseases]. Gastroenterologia 2023;57(2):115-22. Ukrainian. doi: https://doi.org/10.22141/2308-2097.57.2.2023.541
  14. Brown EM, Clardy J, Xavier RJ. Gut microbiome lipid metabolism and its impact on host physiology. Cell Host Microbe. 2023;31(2):173-86. doi: https://doi.org/10.1016/j.chom.2023.01.009
  15. Walker RL, Vlamakis H, Lee JW, Besse LA, Xanthakis V, Vasan RS, et al. Population study of the gut microbiome: associations with diet, lifestyle, and cardiometabolic disease. Genome Med. 2021;13(1):188. doi: https://doi.org/10.1186/s13073-021-01007-5
  16. Perino A, Demagny H, Velazquez-Villegas L, Schoonjans K. Molecular Physiology of Bile Acid Signaling in Health, Disease, and Aging. Physiol Rev. 2021;101(2):683-731. doi: https://doi.org/10.1152/physrev.00049.2019
  17. Grylls A, Seidler K, Neil J. Link between microbiota and hypertension: Focus on LPS/TLR4 pathway in endothelial dysfunction and vascular inflammation, and therapeutic implication of probiotics. Biomed Pharmacother. 2021;137:111334. doi: https://doi.org/10.1016/j.biopha.2021.111334
  18. An H, Qian C, Cao X. Regulation of Toll-like receptor signaling in the innate immunity. Sci China Life Sci. 2010;53(1):34-43. doi: https://doi.org/10.1007/s11427-010-0011-x
  19. Sokolova M, Yang K, Hansen SH, Louwe MC, Kummen M, Hov J, et al. NLRP3 inflammasome deficiency attenuates metabolic disturbances involving alterations in the gut microbial profile in mice exposed to high fat diet. Sci Rep. 2020;10(1):21006. doi: https://doi.org/10.1038/s41598-020-76497-1
  20. Simon MC, Reinbeck AL, Wessel C, Heindirk J, Jelenik T, Kaul K, et al. Distinct alterations of gut morphology and microbiota characterize accelerated diabetes onset in nonobese diabetic mice. J. Biol Chem. 2020;295(4):969-80. doi: https://doi.org/10.1074/jbc.RA119.010816
  21. Zhuang K, Shu X, Meng W, Zhang D. Blended-protein changes body weight gain and intestinal tissue morphology in rats by regulating arachidonic acid metabolism and secondary bile acid biosynthesis induced by gut microbiota. Eur J Nutr. 2024;63(5):1605-21. doi: https://doi.org/10.1007/s00394-024-03359-1
  22. Yang G, Wei J, Liu P, Zhang Q, Tian Y, Hou G, et al. Role of the gut microbiota in type 2 diabetes and related diseases. Metabolism. 2021;117:154712. doi: https://doi.org/10.1016/j.metabol.2021.154712
  23. Moughaizel M, Dagher E, Jablaoui A, Thorin C, Rhimi M, Desfontis JC, et al. Long-term high-fructose high-fat diet feeding elicits insulin resistance, exacerbates dyslipidemia and induces gut microbiota dysbiosis in WHHL rabbits. PLoS ONE. 2022;17(2):e0264215. doi: https://doi.org/10.1371/journal.pone.0264215
  24. Chang AY, Skirbekk VF, Tyrovolas S, Kassebaum NJ, Dieleman JL. Measuring population ageing: an analysis of the global burden of disease study 2017. Lancet Public Health. 2019;4(3):e159-67. doi: https://doi.org/10.1016/s2468-2667(19)30019-2
  25. Christovich A, Luo XM. Gut Microbiota, Leaky Gut, and Autoimmune Diseases. Front Immunol. 2022;13:946248. doi: https://doi.org/10.3389/fimmu.2022.946248
  26. Li X, Fan Z, Cui J, Li D, Lu J, Cui X, et al. Trimethylamine n-oxide in heart failure: A meta-analysis of prognostic value. Front Cardiovasc Med. 2022;9:817396. doi: https://doi.org/10.3389/fcvm.2022.817396
  27. Cao C, Yue S, Lu A, Liang C. Host-Gut Microbiota Metabolic Interactions and Their Role in Precision Diagnosis and Treatment of Gastrointestinal Cancers. Pharmacol Res. 2024;207:107321. doi: https://doi.org/10.1016/j.phrs.2024.107321
  28. Hou Y, Zhai X, Wang X, Wu Y, Wang H, Qin Y, et al. Research progress on the relationship between bile acid metabolism and type 2 diabetes mellitus. Diabetol Metab Syndr. 2023;15(1):235. doi: https://doi.org/10.1186/s13098-023-01207-6
  29. He J, Zhang P, Shen L, Niu L, Tan Y, Chen L, et al. Short-chain fatty acids and their association with signalling pathways in inflammation, glucose and lipid metabolism. Int J Mol Sci. 2020;21(17):6356. doi: https://doi.org/10.3390/ijms21176356
  30. Rodríguez-Daza MC, Daoust L, Boutkrabt L, Pilon G, Varin T, Dudonné S, et al. Wild blueberry proanthocyanidins shape distinct gut microbiota profile and influence glucose homeostasis and intestinal phenotypes in high-fat high-sucrose fed mice. Sci Rep. 2020;10(1):2217. doi: https://doi.org/10.1038/s41598-020-58863-1
  31. Zheng X, Chen T, Jiang R, Zhao A, Wu Q, Kuang J, et al. Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism. Cell metabolism. 2021;33(4):791-803. doi: https://doi.org/10.1016/j.cmet.2020.11.017
  32. Wu L, Tang Z, Chen H, Ren Z, Ding Q, Liang K, et al. Mutual interaction between gut microbiota and protein/amino acid metabolism for host mucosal immunity and health. Anim Nutr. 2021;7(1):11-6. doi: https://doi.org/10.1016/j.aninu.2020.11.003
  33. Nemet I, Li XS, Haghikia A, Li L, Wilcox J, Romano KA, et al. Atlas of gut microbe-derived products from aromatic amino acids and risk of cardiovascular morbidity and mortality. Eur Heart J. 2023;44(32):3085-96. doi: https://doi.org/10.1093/eurheartj/ehad333
  34. Cosentino RG, Churilla JR, Josephson S, Molle-Rios Z, Hossain MJ, Prado WL, et al. Branched-chain amino acids and relationship with inflammation in youth with obesity: a randomized controlled intervention study. J Clin Endocrinol Metab. 2021;106(11):3129-39. doi: https://doi.org/10.1210/clinem/dgab538
  35. Rahman MM, Islam F, -Or-Rashid MH, Mamun AA, Rahaman MS, Islam MM, et al. The Gut Microbiota (Microbiome) in Cardiovascular Disease and Its Therapeutic Regulation. Front Cell Infect Microbiol. 2022;12:903570. doi: https://doi.org/10.3389/fcimb.2022.903570
  36. Ikeda T, Nishida A, Yamano M, Kimura I. Short-chain fatty acid receptors and gut microbiota as therapeutic targets in metabolic, immune, and neurological diseases. Pharmacol Ther. 2022;239:108273. doi: https://doi.org/10.1016/j.pharmthera.2022.108273
  37. Zhen J, Zhou Z, He M, Han HX, Lv EH, Wen PB, et al. The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases. Front Endocrinol (Lausanne). 2023;14:1085041. doi: https://doi.org/10.3389/fendo.2023.1085041
  38. Ringel C, Dittrich J, Gaudl A, Schellong P, Beuchel CF, Baber R, et al. Association of plasma trimethylamine N-oxide levels with atherosclerotic cardiovascular disease and factors of the metabolic syndrome. Atherosclerosis. 2021;335:62-7. doi: https://doi.org/10.1016/j.atherosclerosis.2021.09.026
  39. Kazemian N, Mahmoudi M, Halperin F, Wu JC, Pakpour S. Gut microbiota and cardiovascular disease: opportunities and challenges. Microbiome. 2020;8(1):36. doi: https://doi.org/10.1186/s40168-020-00821-0
  40. Koval SM, Yushko KO, Snihurska IO. [Gut microbiota and arterial hypertension (a literature review)]. Zaporozhye medical journal. 2020;22(4):561-7. Ukrainian. doi: https://doi.org/10.14739/2310-1210.2020.4.208409
  41. Juste C, Gérard P. Cholesterol-to-coprostanol conversion by the gut microbiota: what we know, suspect, and ignore. Microorganisms. 2021;9(9):1881. doi: https://doi.org/10.3390/microorganisms9091881
  42. Liu Y, Xiao H, Wang Z, Pan Q, Zhao X, Lu B. Interactions between dietary cholesterol and intestinal flora and their effects on host health. Crit Rev Food Sci Nutr. 2025;65(3):494-506. doi: https://doi.org/10.1080/10408398.2023.2276883
  43. Jin L, Shi X, Yang J, Zhao Y, Xue L, Xu L, et al. Gut microbes in cardiovascular diseases and their potential therapeutic applications. Protein Cell. 2021;12(5):346-59. doi: https://doi.org/10.1007/s13238-020-00785-9
  44. Piccioni A, de Cunzo T, Valletta F, Covino M, Rinninella E, Raoul P, et al. Gut Microbiota and Environment in Coronary Artery Disease. Int J Environ Res Public Health. 2021;18(8):4242. doi: https://doi.org/10.3390/ijerph18084242
  45. He X, Zhao S, Li Y. Faecalibacterium prausnitzii: A next-generation probiotic in gut disease improvement. Can J Infect Dis Med Microbiol. 2021;2021:6666114. doi: https://doi.org/10.1155/2021/6666114
  46. Novakovic M, Rout A, Kingsley T, Kirchoff R, Singh A, Verma V, et al. Role of gut microbiota in cardiovascular diseases. World J Cardiol. 2020;12(4):110-22. doi: https://doi.org/10.4330/wjc.v12.i4.110
  47. Tousoulis D, Guzik T, Padro T, Duncker DJ, De Luca G, Eringa E, et al. Mechanisms, therapeutic implications, and methodological challenges of gut microbiota and cardiovascular diseases: a position paper by the ESC Working Group on Coronary Pathophysiology and Microcirculation. Cardiovasc Res. 2022;118(16):3171-82. doi: https://doi.org/10.1093/cvr/cvac057
  48. Wu H, Chiou J. Potential Benefits of Probiotics and Prebiotics for Coronary Heart Disease and Stroke. Nutrients. 2021;13(8):2878. doi: https://doi.org/10.3390/nu13082878
  49. El Hage R, Al-Arawe N, Hinterseher I. The Role of the Gut Microbiome and Trimethylamine Oxide in Atherosclerosis and Age-Related Disease. Int J Mol Sci. 2023;24(3):2399. doi: https://doi.org/10.3390/ijms24032399
  50. Al-Rashidi HE. Gut microbiota and immunity relevance in eubiosis and dysbiosis. Saudi J Biol Sci. 2022;29(3):1628-43. doi: https://doi.org/10.1016/j.sjbs.2021.10.068
  51. Britton RA, Hoffmann DE, Khoruts A. Probiotics and the Microbiome-How Can We Help Patients Make Sense of Probiotics? Gastroenterology. 2021;160(2):614-23. doi: https://doi.org/10.1053/j.gastro.2020.11.047

Downloads

Additional Files

Published

2025-06-17

How to Cite

1.
Bogoslav TV. A cardiometabolic patient and microbiota. Zaporozhye Medical Journal [Internet]. 2025Jun.17 [cited 2026May16];27(3):233-7. Available from: https://zmj.zsmu.edu.ua/article/view/321475

Issue

Vol. 27 No. 3 (2025)

Section

Review

License

Copyright (c) 2025 T. V. Bogoslav

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons